tbuckley/cabot-search huggingface dataset:
THU0080 Lipid Testing and Management among Rheumatoid Arthritis Patients Compared To Patients with Diabetes and The General Population: Table 1.
Authors: I. Navarro-Millan, S. Yang, L. Chen, M.M. Safford, H. Yun, J. Zhang, P. Muntner, K. Saag, J.R. Curtis
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patients with rheumatoid arthritis (RA) have high coronary heart disease (CHD) burden. Limited data suggest that these patients may be screened less frequently than other patients with similar CHD risk. <h3>Objectives</h3> To evaluate the rate of lipid testing and management among RA patients and compare it both to the general population and diabetes (DM) patients. <h3>Methods</h3> We used a mix of private and public health plans claims data from 2006 to 2010 with medical and pharmacy coverage. Eligible participants were required to 1) have at least 12 months of continuous medical and pharmacy coverage (baseline period), and 2) have 2+ physician diagnosis and relevant medications to categorize them as having 1) RA and DM; 2) RA only; 3) DM only; 4) Neither RA nor DM. Patients with prevalent myocardial infarction (MI)/stroke/CHD during baseline were excluded. We calculated the proportion of patients with low density lipoprotein (LDL) lab test. In a subgroup analysis, we determined the proportion of patients with lab results available with LDL ≥130 mg/dL that initiated treatment with statins. We use chi-square tests to compare differences between the 4 cohorts in the proportion tested for LDL and initiating statins. <h3>Results</h3> There were 428,109 eligible patients distributed between the 4 cohorts (Table). Overall, 60% were women. The overall age distribution was: 12% ≤40; 29%, 41–65; and 59% &gt;65 years old. RA patients were less frequently tested for LDL compared to DM patients, with or without RA (p-value &lt;0.001 for all comparisons). Conditional on having LDL ≥130 mg/dL, RA patients were less likely to be started on a statin compared to DM patients (p-value &lt;0.001), and were marginally more likely to be initiated on statins compared to the general population (p-value =0.045). There was no difference in the statin prescription trend after an LDL ≥130 mg/dL between DM and RA patients compared to only RA patients (p-value =0.083) <h3>Conclusions</h3> RA patients are less frequently screened and managed for hyperlipidemia compared DM patients. Despite higher CHD risks in RA patients, hyperlipidemia screening and treatment rates in RA patients were no better than the general population. Further studies to investigate the reasons and potential interventions to ameliorate this care gap among RA patients are needed. <h3>Disclosure of Interest</h3> None declared
Lack of evidence for interventions offered in UK fertility centres
Authors: Carl Heneghan, E A Spencer, N Bobrovitz, D R J Collins, D Nunan, A Plüddemann, OA Gbinigie, I Onakpoya, J O’Sullivan, A Rollinson, A Tompson, B Goldacre, K R Mahtani
Journal: BMJ (2016)

Infertility affects about one in seven couples, many of whom seek medical help to have a child. 1 Although numerous new fertility interventions and products have been developed over the past decade, there are concerns that some might not be evidence based and that some clinics may be offering additional services that are not based on the most up-to-date research. 2 In vitro fertilisation (IVF) is expensive-a single cycle can cost £5000 (€5800; $6200)-and places considerable financial burden on patients, especially as 59% of procedures are not NHS funded. 3 On top of this UK fertility treatment centres offer a range of additional investigations and treatments, 4 costing from £50 for a single screening blood test to as much as £8000 for egg freezing packages (box 1).Guidance from the UK regulator, the Human Fertilisation and Embryology Authority (HFEA), suggests questions that couples might want to ask before deciding on treatment. 2These include: Is this treatment recommended by the National Institute for Health and Care Excellence (NICE) and, if not, why not?Has this treatment been subjected to randomised controlled clinical trials that show it is effective and is there a Cochrane review available?Are there any adverse effects or risks (known or potential) of the treatment? 2 Given concerns over the evidence base for fertility treatments and the implications for patients we set out to answer these questions.
Second premolar agenesis is associated with mandibular form: a geometric morphometric analysis of mandibular cross-sections
Authors: Michael H Bertl, Kristina Bertl, Manuel Wagner, André Gahleitner, Andreas Stavropoulos, Christian Ulm, Philipp Mitteroecker
Journal: International Journal of Oral Science (2016)

The aim of this study was to compare mandibular form (i.e., size and shape) between patients with agenesis of the lower second premolar (P2) and a control group with no agenesis. Three hypotheses were tested: (H1) agenesis causes a change in mandibular morphology because of inadequate alveolar ridge development in the area of the missing tooth (mandibular plasticity); (H2) agenesis is caused by spatial limitations within the mandible (dental plasticity); and (H3) common genetic/epigenetic factors cause agenesis and affect mandibular form (pleiotropy). A geometric morphometric analysis was applied to cross-sectional images of computed tomography (CT) scans of three matched groups (n=50 each): (1) regularly erupted P2; (2) agenesis of P2 and the primary second molar in situ; and (3) agenesis of P2 and the primary second molar missing for >3 months. Cross-sections of the three areas of interest (first premolar, P2, first molar) were digitized with 23 landmarks and superimposed by a generalized Procrustes analysis. On average, the mandibular cross-sections were narrower and shorter in patients with P2 agenesis compared with that in the control group. Both agenesis groups featured a pronounced submandibular fossa. These differences extended at least one tooth beyond the agenesis-affected region. Taken together with the large interindividual variation that resulted in massively overlapping group distributions, these findings support genetic and/or epigenetic pleiotropy (H3) as the most likely origin of the observed covariation between mandibular form and odontogenesis. Clinically, reduced dimensions and greater variability of mandibular form, as well as a pronounced submandibular fossa, should be expected during the treatment planning of patients with P2 agenesis. Common developmental cues probably underlie both premolar tooth agenesis and the shape of the jawbone. About 3% of the population never develop a lower second premolar tooth. What is the relationship between missing teeth and jawbone shape? To find out, a team led by Michael Bertl from the University Clinic of Dentistry in Vienna, Austria, measured anatomical landmark coordinates in the jawbones of 150 patients. They found that people missing a lower second premolar, whether or not their primary second molars had been extracted, had morphological differences that extended across the whole jawbone, pointing to genetic and epigenetic effects affecting the growth of both craniofacial bones and teeth.
Pulmonary Infiltrates in NHL Patients Receiving Rituximab Combined with Chemotherapy: 18F-Fluorodeoxyglucose Positron Emission Tomography and CT (PET-CT) Analysis and Clinical Correlates.
Authors: Yael C Cohen, Tamar Cohen-Berger, Lora Eshel, Dorit Stern, Osnat Bairey, Pia Raanani, Hanna Bernstine, Ofer Shpilberg, David Groshar
Journal: Blood (2009)
Identification of MLL-Fusion/Myc⊣miR-26a/Mir-29a⊣Tet1 Signaling Circuit in MLL-Rearranged Leukemia
Authors: Hao Huang, Xi Jiang, Jinhua Wang, Yuanyuan Li, Ping Chen, Stephen Arnovitz, Shenglai Li, Yungui Wang, Hengyou Weng, Mary Elizabeth Neilly, Zejuan Li, Jianjun Chen
Journal: Blood (2014)
Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice
Authors: Gladys Ferrere, Laura Wrzosek, Frédéric Cailleux, Williams Turpin, Virginie Puchois, Madeleine Spatz, Dragos Ciocan, Dominique Rainteau, Lydie Humbert, Cindy Hugot, Françoise Gaudin, Marie-Louise Noordine, Véronique Robert, Dominique Berrebi, Muriel Thomas, Sylvie Naveau, Gabriel Perlemuter, Anne-Marie Cassard
Journal: Journal of Hepatology (2016)
In Vivo T Cell Depletion with Antithymocyte Globulin or Alemtuzumab for Unrelated Donor Stem Cell Transplantation with Reduced Intensity Conditioning: Results of a Multicenter Randomized Phase II Clinical Trial (The Global Study) From the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)
Authors: Alessandro Rambaldi, Alessandra Algarotti, Caterina Micò, Paolo Corradini, Michele Falda, Emilio Paolo Alessandrino, Renato Fanin, Elena Tagliaferri, Luca Castagna, Nicola Mordini, Simona Sica, Stella Santarone, Massimo Pini, Fiammetta Natalino, Simona Pollichieni, Nicoletta Sacchi, Marco Scarano, Arianna Masciulli, Roberto Marchioli, Andrea Bacigalupo, Alberto Bosi
Journal: Blood (2012)
The Prognostic Effect of High WT1 Gene Expression in Pediatric AML Depends on WT1 SNP rs16754 Status: A Report From the Children's Oncology Group (COG)
Authors: Phoenix A. Ho, Todd A. Alonzo, Robert B. Gerbing, Julia Kuhn, Jessica A. Pollard, Betsy A. Hirsch, Susana C. Raimondi, Alan S. Gamis, Soheil Meshinchi
Journal: Blood (2011)
OP0019-HPR Effectiveness of A Progressive Resistance Strength Program on Hand Osteoarthritis: A Randomised Controlled Trial
Authors: M.V. Nery, A. Jones, F. Jennings, M.C. Souza, J. Natour
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Hand osteoarthritis is highly prevalent, affecting 55–70% of the population over 55 years with an age-related progressive increase. The OA of interphalangeal and carpometacarpal joints may have varying degrees of deformity associated with pain, decreased of grip and pinch strength, decreased range of motion and functional impairment. Effects of exercise in HOA in pain, function and strength is stiill unclear and based on experts opinions. <h3>Objectives</h3> To assess the effectiveness of progressive resistance strength training program on pain, function and strength in hand OA patients. <h3>Methods</h3> Diagnostic of hand OA according to ACR of at least 1year,over 50 years, both genders, pain in IF joints between 3–8 cm on NPS. Sixty patients who met the eligibility criteria were randomised into exercise group (EG) and control group (CG). Both groups performed a session regarding joint protection and energy conservation before randomisation. The EG performed a progressive resistance strength training program for intrinsic muscles of the hand for 12 weeks. The outcome measures were NPS, AUSCAN and COCHIN for hand function; grip and pinch strength using hydraulic hand dynamometers and patient satisfaction using a Likert scale. A blinded evaluator performed the evaluations at baseline, 6 and 12 weeks after treatment baseline. <h3>Results</h3> The groups were homogeneous at baseline except for the key pinch strength for nondominant hand and palmar pinch strength for both hands. The comparison between groups using repeated measures ANOVA shows an statistically difference between groups in AUSCAN (total score, p=0.005$;$ pain, p=0.006 and function, p=0.047), COCHIN (p=0.042) and Likert scale (p=0.001) with better results for the EG. Results were presented in table 1. <h3>Conclusions</h3> This progressive resistance strength training program was effective for pain, function, and treatment satisfaction for patients with hand OA. <h3>Disclosure of Interest</h3> None declared
Adoptive Immunotherapy with Haploidentical Kir Ligand-Mismatched Natural Killer Cells In Elderly High Risk Acute Myeloid Leukemia Patients: Biological and Clinical Results of A Pilot Study
Authors: Antonio Curti, Loredana Ruggeri, Alessandra D'Addio, Andrea Bontadini, Valeria Giudice, Elisa Dan, Maria Rosa Motta, Simonetta Rizzi, Sara Trabanelli, Elena Urbani, Giovanni Martinelli, Stefania Paolini, Fiorenza Fruet, Alessandro Isidori, Beatrice Casadei, Giuseppe Bandini, Michele Baccarani, Andrea Velardi, Roberto M. Lemoli
Journal: Blood (2010)
SAT0305 Neutrophil Extracellular Traps Markers Are Elevated in Patients with Systemic Lupus Erythematosus
Authors: I. Jeremic, B. Bonaci Nikolic
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Impaired removal of apoptotic waste in patients with systemic lupus erythematosus-SLE has been long known as important factor that trigger autoimmune response. Neutrophil extracellular traps could be another source of autoantigens in patients with SLE. <h3>Methods</h3> We analysed sera from 84 SEL patients (60 patients had one sample and 24 patients were followed 2 or 3 times) and 50 healthy blood donors. Serum levels of myeloperoxidase, B-cell activating factor-BAFF, cell free DNA, complement components C3 and C3, antibody to dsDNA by CLIFT end ELISA assays, netolitic activity and DNAse I were measured. <h3>Results</h3> Patients with SLE had higher cfDNA (1.69±0.23 vs. 1.42±031 ng/mL, p=0.0003), MPO activity (p&lt;0.05) and BAFF levels (160735±2353.23 vs. 891.16±184.31, p&lt;0.05). DNAse concentration was also lower in healthy controls (5.84±5.72 vs. 9.38±6.97 pg/mL, p&lt;0.05). BAFF showed strong correlation with anti-dsDNA antibodies determined by ELISA method (ρ=0.564, p=0.000), MPO activity (ρ=0.256, p=0.021), DNAse I concentration (ρ=0.27, p=0.012) and cfDNA concentration (ρ=0.262, p=0.014). MPO activity showed correlations with cfDNA levels (ρ=0.386, p=0.001), DNAse concentration (ρ=0.501, p=0.000), and anti-MPO antibodies (ρ=0.293, p=0.006). Cell free DNA levels additionally correlated with DNAse activity (ρ=0.288, p=0.007) as well with netolytic activity (ρ=0.244, p=0.026). <h3>Conclusions</h3> Increased NETs9 footprints (myeloperoxidase and cfDNA) are present in lupus sera. As probably compensatory mechanism increased DNAse I concentrations also were found in lupus sera. NET burden is followed by production of various antibodies recognizing different NET structures. <h3>Disclosure of Interest</h3> None declared
SAT0643-HPR Points To Consider for Health Professionals Undertaking Musculoskeletal Ultrasound for Rheumatic and Musculoskeletal Diseases: Progress of A Eular Task Force
Authors: H.J. Siddle, P. Mandl, D. Aletaha, T.P. Vliet Vlieland, M. Backhaus, P. Cornell, M.A. D'Agostino, K. Ellegaard, A. Iagnocco, B. Jakobson, T. Jasinski, N.H. Kildal, M. Lehner, I. Möller, G.M. Supp, P. O'Connor, A.C. Redmond, E. Naredo, R.J. Wakefield
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Musculoskeletal ultrasound (MSUS) has evolved into an important method for identifying musculoskeletal abnormalities, confirming the diagnosis in patients with suspected inflammatory arthritis, monitoring therapeutic response, influencing clinical decision making and guiding interventions. The role of the non-medical health professional has advanced with many health professionals undertaking training and using MSUS to extend their scope of practice. Guidelines to support training for rheumatologists have been identified but currently there are not any recommendations to support the education and training needs of non-medical health professionals using MSUS. <h3>Objectives</h3> The EULAR Task Force was established to reach a consensus on the role and education and training needs of non-medical health professionals undertaking MSUS for the management of patients with rheumatic and musculoskeletal diseases (RMDs). <h3>Methods</h3> The EULAR Task Force comprised an expert group from 11 European countries. The Task Force met twice and included rheumatologists, nurses, physiotherapists, a radiologist, radiographer and podiatrist with patient representation. In the first meeting the aims of the Task Force were defined and fourteen research questions were developed. This was followed by a comprehensive systematic search of the literature to identify publications on the role of health professionals using MSUS, their competency requirements and training undertaken. During the second meeting the Task Force were presented with the results of the literature review which supported the formulation and consensus of "points to consider". The level of agreement between task force members for each "point to consider" was determined after the second meeting. <h3>Results</h3> In total, seven "points to consider" were formulated. Two points covered the role and scope of health professionals using musculoskeletal ultrasound and one point addressed the application and feasibility in daily practice. Three "points to consider" focused on the training and competency required by health professionals and the final point addressed the added value in daily practice. The strength of the "points to consider" was D based on the category of evidence (3–4). A high level of agreement (range 9.0–9.7) was achieved between Task Force members. Additionally, the Task Force agreed upon eight topics for the future research agenda. <h3>Conclusions</h3> Seven "points to consider" for health professionals using MSUS for the management of patients with RMDs were developed using a combination of research-based evidence and expert consensus approach. <h3>Disclosure of Interest</h3> None declared
Apoptosis and Proliferation Synergistically Determine Overall Survival in Chronic Lymphocytic Leukemia (CLL)
Authors: Giovanni Del Poeta, Michele Dal Bo, Francesco Buccisano, Federico Pozzo, Maria Ilaria Del Principe, Pietro Bulian, Davide Rossi, Adriano Venditti, Paolo de Fabritiis, Gianluca Gaidano, Sergio Amadori, Valter Gattei
Journal: Blood (2015)
THU0611 Subjective Well-Being of Japanese RA Patients Who Reach Treatment Target Is Higher than The Japanese Average
Authors: G. Kageyama, A. Onishi, Y. Ueda, Y. Kamei, H. Yamada, Y. Ichise, D. Waki, I. Naka, K. Tsuda, T. Okano, S. Takahashi, M. Nishida, K. Akashi, K. Nishimura, S. Sendo, Y. Kogata, J. Saegusa, A. Morinobu
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Subjective Well-Being (SWB) refers to a construct which includes one9s emotional responses, domain satisfactions, and global judgments of life satisfaction. Many variables such as age, sex, income, employment and marital status are related to SWB. Being healthy is also an important factor of SWB. RA is a chronic illness which is considered to influence SWB. However, little is known about the impact of RA on SWB. <h3>Objectives</h3> To evaluate the SWB of Japanese RA patients and identify factors that associate with SWB. <h3>Methods</h3> This study was done in cooperation with the Cabinet Office Government of Japan Economic and Social Research Institute. This institute had previously conducted the “Well-being studies 2014” surveying the SWB of randomly selected Japanese citizens. In this survey, SWB was determined by having the participants rate their happiness between 10 (Very happy) and 0 (very unhappy). The Well-being studies 2014 also included a questionnaire consisting of 56 questions covering topics closely associated with well-being such as socioeconomic and health status. The same survey was done for RA patients at Kobe University Hospital and clinical data including disease duration, stage, class, disease activity, HAQ, complications and the therapeutic drug was also collected at the same time. <h3>Results</h3> Multivariate analysis on data including RA patients (n=339) and Japanese controls (n=7690) revealed that RA patients with high or moderate disease activity had similar SWB scores as Japanese controls. However, the SWB of RA patients with remission or low disease activity were higher than Japanese controls. Age, sex, marital status, presence of child, household income, financial leeway, working status, psychological distress (Kessler 6 scale), self-assessment of health, and social connection were all associated with SWB. <h3>Conclusions</h3> Japanese RA patients may be able to get higher SWB than Japanese controls by achieving treatment target. <h3>Disclosure of Interest</h3> None declared
THU0643-HPR Prevalence of Foot Problems in People with Inflammatory Arthritis in Singapore
Authors: K. Carter, M. Lahiri, P. Cheung, A. Santosa, K. Rome
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Foot problems are highly prevalent in people with inflammatory arthritis [1]. Podiatry intervention can significantly reduce foot pain and disability [2]. Most knowledge of the epidemiology of foot involvement is based on studies from the UK, Europe and New Zealand [1,3,4] with limited evidence relating to the podiatric need of people with inflammatory arthritis in Singapore. <h3>Objectives</h3> To evaluate the prevalence of foot problems in people with inflammatory arthritis in Singapore. <h3>Methods</h3> People with inflammatory arthritis were recruited from the rheumatology outpatient clinic of a large public hospital in Singapore. Disease and clinical characteristics included age, sex, disease duration, BMI, current disease modifying anti-rheumatic drug (DMARD) medications, ESR and CRP. Foot pain was measured using a 10cm visual analogue scale. The Leeds Foot Impact Scale (LFIS) [5] was used to evaluate foot impairment and disability and the Modified Health Assessment Questionnaire (MHAQ) was used to assess global function [6]. Foot assessments were conducted and prevalence of foot deformity was ascertained. <h3>Results</h3> We recruited 101 people with inflammatory arthritis, of which 50% were female. The mean of age was 52±15 years, and the mean disease duration was 9.3±0.3 years. The most commonly reported inflammatory arthritis conditions were rheumatoid arthritis (46%), spondyloarthritis (18%) and gout (15%). Most (61%) were overweight with a mean BMI of 27.2±5.4 kg/m<sup>2</sup>. 42% of all participants were on a current prescription of methotrexate and 52% were receiving a combination DMARD therapy. Only 4% were receiving biologic therapy. The mean ESR was 31.6±21.2mg/hr and mean CRP was 27.4±32.2mm/L. The mean of the total LFIS was 17±13 indicating moderate to severe levels of foot impairment and activity limitation. The mean MHAQ score was 0.25±0.36. Over 80% of participants experienced foot problems during the course of their condition, and 48% reported current foot pain. The mean pain score was 5.0±2.3. Despite the high prevalence of foot problems (81%), only 21 participants (21%) had been referred to a podiatrist. <h3>Conclusions</h3> This is the first study to investigate the prevalence of foot problems in people with inflammatory arthritis in Singapore. The majority of the participants reported foot problems, but had not been referred to a podiatry service. Findings from this study will be used to improve referral rates, service provision and quality of patient care. <h3>References</h3> Grondal L, et al. Acta Orthop. 2008; 79:257–261. Woodburn J, et al. J Rheumatology. 2002; 29:1377–83. Otter S, et al. Clinical Rheumatology. 2010; 29:255–271. Rome K, et al. J Foot Ankle Res. 2009; 2:16. Helliwell P, et al. Arthritis Rheumatology. 2005; 53:418–422. Pincus T, et al. Arthritis Rheumatology. 1983; 26:1346–53. <h3>Disclosure of Interest</h3> None declared